Subscribe
shutterstock_733304062_casimiro_pt
Casimiro PT / Shutterstock.com
26 July 2019AmericasSarah Morgan

Bio-Rad wins injunction against 10X Genomics

Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York